Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05836948 Not yet recruiting - Clinical trials for Advanced Solid Tumor

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Start date: May 1, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

NCT ID: NCT05834426 Not yet recruiting - Cancer Clinical Trials

Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers

Start date: September 1, 2023
Phase:
Study type: Observational

The goal of this observational study is to determine the plasma metabolomic profile in diffuse large B-cell lymphoma and high-grade B lymphomas patients before, during and after treatment by ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)

NCT ID: NCT05831033 Not yet recruiting - Solid Tumor Clinical Trials

Safety and Efficacy of an Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients With Advanced Solid Tumors

Start date: May 15, 2023
Phase: Early Phase 1
Study type: Interventional

Multicenter, single arm, non-randomized, prospective, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (BEN101) followed by IL-2 after a non-myeloablative (NMA) lymphodepletion preparative regimen for the treatment of patients with recurrent and/or metastatic solid tumor.

NCT ID: NCT05830045 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Phase I Study of QLP2117 in Subjects With Advanced Solid Tumors

Start date: April 20, 2023
Phase: Phase 1
Study type: Interventional

This is the first in human study of QLP2117. To evaluate the Safety, Pharmacokinetics, Immunogenicity and Efficacy of QLP2117 in patients with advanced solid tumors.

NCT ID: NCT05829616 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of QLS12004 in Patients With Advanced Solid Tumors

Start date: April 17, 2023
Phase: Phase 1
Study type: Interventional

This study is a single-arm, open, dose-escalation, and dose-expansion phase I clinical trial of QLS12004 in patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of QLS12004 in subjects with advanced solid tumors.

NCT ID: NCT05824663 Not yet recruiting - Clinical trials for Advanced Solid Tumor

A Study Evaluating the Safety, Tolerance and Anti-tumor Activity of HBM1020 in Subjects With Advanced Solid Tumors

Start date: May 2023
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the safety and tolerability of the study drug HBM1020 which contains two parts. Part 1 will enroll solid tumor participants and Part 2 will enroll renal cell carcinoma (RCC) and colorectal adenocarcinoma (CRC).

NCT ID: NCT05824494 Not yet recruiting - Cervical Cancer Clinical Trials

Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint Inhibitors

Start date: June 2023
Phase: Phase 2
Study type: Interventional

This is a phase II trial of combination therapy of cadonilimab(Bispecific Anti-PD-1/CTLA-4 Antibody) plus nab-Paclitaxel in patients with recurrent or metastatic cervical cancer that had failed PD-1/PD-L1 blockade therapy. As a bispecific antibody against PD-1 and CTLA-4, cardonirimab can not only induce the production of a large number of T cells in the early stage of immune response by antagonizing CTLA-4, but also block PD-1 and PD-L1/L2 combination. Thereby restoring the killing function of T cells to tumor cells and reducing the exhaustion of T cells.The hypothesis is the combination of cadonilimab and nab-Paclitaxel will overcome PD-1/PD-L1 blockade-resistance to enhance the response of patients with persistant, recurrent or metastatic cervical cancer.

NCT ID: NCT05821595 Not yet recruiting - Solid Tumor Clinical Trials

JYB1907 in Subjects With Advanced Solid Tumors

Start date: July 31, 2023
Phase: Phase 1
Study type: Interventional

A Phase I, Multi-center, Open-label Study with Dose-escalation and Multiple Expansion Cohorts to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of JYB1907 in Subjects with Advanced Solid Tumors

NCT ID: NCT05820126 Not yet recruiting - Clinical trials for Hematologic Malignancy

Cold Versus Room Temperature Storage of Platelets for Bleeding in Hematologic Malignancy - a Pilot Trial

CoVeRTS-HM
Start date: September 5, 2023
Phase: Phase 2
Study type: Interventional

This is a pilot trial to discover the feasibility of recruiting 50 pts over the course of 12 months. The trial is testing the efficacy of using cold-stored vs. room temperature stored (current standard of care) platelets to treat bleeding in persons with hematological disorders and thrombocytopenia.

NCT ID: NCT05804864 Not yet recruiting - Clinical trials for Advanced Solid Tumors

A Study of KM501 in Patients With Solid Tumors

Start date: April 2023
Phase: Phase 1
Study type: Interventional

A single-arm, open, multicenter Phase I study to evaluate the safety, tolerability, pharmacokinetic profile, and efficacy of the KM501 double-antibody ADC in subjects with advanced solid tumors that express, amplify, or mutate HER2